TherapeuticsMD, Inc. (TXMD)

Kritische 8-K Meldungen

DatumMeldungSchwereFilingAuszug
06.01.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSECnclude (i) additional information required under Item 5.02 in connection with management transitions following the Trans

Stammdaten

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Unternehmen & Branche

NameTherapeuticsMD, Inc.
TickerTXMD
CIK0000025743
BoerseUS
SektorHealthcare
IndustrieDrug Manufacturers - Specialty & Generic
SIC2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP
ISIN
TypCommon Stock
Marktkapitalisierung25,1 Mio. USD
Beta0,56
Dividendenrendite0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K-569,000-0.0537,656,00026,876,000
2025-09-3010-Q152,0000.0138,671,00027,444,000
2025-06-3010-Q551,0000.0538,504,00027,292,000
2025-03-3110-Q-653,000-0.0638,236,00026,740,000
2024-12-3110-K1,761,000-2,181,000-0.1938,822,00027,370,000
2024-09-3010-Q-609,000-0.0527,094,000
2024-06-3010-Q-1,090,000-0.0940,126,00027,670,000
2024-03-3110-Q-734,000-0.0628,664,000
2023-12-3110-K1,302,000-10,278,000-0.9943,309,00029,287,000
2023-09-3010-Q-53,000-3,378,000-0.3250,493,00028,052,000
2023-06-3010-Q437,000-2,414,000-0.2453,689,00031,197,000
2023-03-3110-Q416,000-3,603,000-0.3759,601,00032,024,000
2022-12-3110-K69,963,000111,997,00011.9690,458,00035,143,000
2022-09-3010-Q354,000-28,965,000-3.13133,907,000-48,271,000
2022-06-3010-Q348,000112,281,00012.83146,202,000-26,066,000
2022-03-3110-Q695,000-49,021,000-5.70133,381,000-140,580,000
2021-12-3110-K18,678,000-42,960,000-21.66169,472,000-93,621,000
2021-09-3010-K25,406,000-47,420,000
2021-09-3010-Q25,406,000-47,420,000-5.62209,628,000-57,360,000
2021-06-3010-K23,001,000-42,652,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

DatumInsiderRolleTypStückzahlKursWert (USD)ΔTrend
2025-12-23Thompson Tommy GDirectorOpen Market Purchase8,4001.6714,030.52+100,0%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.

Hinweis

Erweitert ×